Wedbush raised the firm’s price target on Arcus Biosciences (RCUS) to $35 from $33 and keeps an Outperform rating on the shares following third quarter results. Recently updated data for casdatifan as monotherapy in heavily pretreated clear cell renal cell carcinoma patients showed a modified progression-free survival of 12.2 months at a median follow-up of 15.2 months, and an objective response rate of 31%, which Wedbush believes, along with promising cabo combination data presented at ASCO 2025, strongly differentiates its profile compared to belzutifan, the firm told investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences price target raised to $56 from $54 at Citi
- Arcus Biosciences price target raised to $28 from $24 at H.C. Wainwright
- Arcus Biosciences Reports Promising Q3 2025 Results
- Arcus Biosciences reports Q3 EPS ($1.27), consensus ($1.29)
- Arcus Biosciences Advances Cancer Treatment with AB801 Study